List view / Grid view

Sheldon Sloan (Abivax)

 

article

Harnessing small molecules to treat chronic inflammatory diseases

Dr Sheldon Sloan, MBE, Chief Medical Officer, Abivax, shares why…

29 May 2024 | By ,

Dr Sheldon Sloan, MBE, Chief Medical Officer, Abivax, shares why the company’s microRNA small molecule treatment could provide long-term efficacy for ulcerative colitis patients, as well as the outlook for using small molecule-based drugs in autoimmune and chronic diseases.